The obvious advantages of MRI-based cell imaging are the high resolution and anatomic details for soft tissue as well as the ability to generate contrast based on a variety of physiological parameters (1, 2). Bio-functionalization of nanoparticles allows visualization of specific cell types by receptor specific uptake or binding, making MRI a powerful tool for molecular imaging (1, 3, 4) . However, a number of issues must be carefully considered for non-invasive in vivo cell imaging in general and for MRI-based cell tracking in particular. Apart from issues related to the relatively low sensitivity of MRI, specificity issues, the stability of MRI contrast agents or the generation of unambiguous contrast, the prevention of toxicity and alterations of cellular processes by the contrast agent and no or minimal influence on the physiological behavior of the cells are of highest importance.
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Many contrast agents are administered in coated or chelated form to reduce toxicity. Contrast agents used for cell labeling and molecular imaging applications are usually clinically approved or tested intensively in cell culture (5, 6) . They are usually well tolerated by various cell types. However, it is known that some of these contrast agents may cause unwanted side effects or become toxic when used in high dosages as required for some experimental applications (1, 7) . Hereby, nano-particles are usually less toxic than lanthanide chelates or manganese based agents.
For in vitro cell labeling applications, an efficient cellular uptake of particles often requires cationic transfection agents, leading to complexes with difficult to control physico-chemical characteristics (8) . Once internalized, the coating and subsequently the entire nanoparticle may be degraded rapidly in lysosomal structures. Many newly developed nano-particles are coated with a large variety of surface molecules such as citrate, synthetic polymers, dendrimers, dimercaptosuccinic acid or phospholipids (for review see 8). Their highly variable physico-chemical properties may result in concomitant interactions of the particles with cells and tissue. Hereby, one have to keep in mind that not all cell types will react similarly to the exposure to those nano-particles, which may for example result in a variance in potentially toxic concentrations of nano-particles. This makes a systematic validation of cytotoxic effects difficult and also resulted in partially contradicting conclusions in literature data (8) . Therefore, cell-nanoparticle interactions and their effect on cell viability and function must be carefully studied in every particular experimental setup.
Immediate toxic effects can easily be tested by growth and viability studies in cell suspensions. Only very few reports found immediate toxic effects of iron oxide based contrast agents in high concentrations (9) . Iron in high concentrations is known to interact with a number of other metabolic pathways and might cause oxidative stress (10, 11) . Interference with the response to normal physiological stimuli (12, 13) , effects on cell migration (14) , influence on the structure of the cytoskeleton (11, 15) and marginal effects on some cell differentiation processes (11, 16) have also been reported for very high concentrations of nano-particles. Utilization of transfection agents affects cytotoxicity not only by influencing the uptake of nanoparticles but have also direct influences on cell viability (17) . While bio-functionalization of nanoparticles aims to decrease cytotoxic effects and improve specificity, for example, by binding to specific receptors on cell membranes, the later might also influence cell functionality by competing with 'natural' substrates.
The most commonly used essays for the validation of cytotoxic effects of nanoparticles are usually cell viability tests. Hereby, survival and cell proliferation are most commonly addressed. Different assays study different properties like cell membrane integrity (trypan blue exclusion assay or lactate dehydrogenase assay), mitochondrial metabolism (MTT assay), cell metabolism (Alamar Blue essay), lysosomal membrane integrity (neutral red), nucleic acid staining (Propidium iodide staining) and others (8) . Also of importance for the evaluation of potential cytotoxic effects of iron oxide based nanoparticles is the determination of reactive oxygen species formation, which can be formed in the acedic environment of lysosomes and may impair the cell plasma membrane, mitochondria and nucleus (8, 11) .
While those tests are essential, they do not address all aspects of cell functionality. Hereby, it is not possible to determine all possible effects on all cell types present in vivo. One has to make a selection based on the targeted cells and most likely biological effects. For example if a contrast agent is supposed to visualize the functionality of cells in the pancreas, tests need to be performed to address for example insulin secretion of beta cells. If nanoparticles are supposed to be accumulated in immune cells, cell functionality can be tested by analyzing the capacity to secrete immunological factors in response to defined microbial stimuli or by testing immune cell activation (for example using dendritic cells). For cells that are able to change their functional status, it is also important to test those cellular changes like the differentiation potential of stem cells by quantitative PCR or flow cytometry (16, 18) or the activation of dendritic cells (19) .
Although some of those effects are marginal or only relevant for extremely high concentrations, it is imperative to determine a safe concentration with no or marginal effects on cell biology also for experimental and pre-clinical applications of nanoparticles. Hereby, generally accepted test protocols and standards are essential. For example, safe concentrations for in vitro labeling of cells with nanoparticles are often expressed by stating nanoparticles present in medium rather than in terms of intracellular nanoparticle concentrations. This however is often of little value and difficult to compare between different cell types and labeling protocols. Furthermore, one has to consider that local amounts of nanoparticles required for in vivo visualization of the targeted tissue or cells are often much lower than the administered amounts of nanoparticles due to dilution after systemic administration (which may result in high local concentrations in organs as the liver or kidney) or, for in vitro labeled, engrafted cells, the dilution of nanoparticles due to continued cell proliferation.
The broad spectrum of different nanoparticle-cell interactions and the great number of possible interferences of the iron oxide cores on various cellular processes drastically impedes any straightforward attempt to assess nanoparticle safety (8) . Issues that need to e addressed in relation to nanoparticle toxicity include immediate effects on cell survival and proliferation, concentrationdependent secondary effects on cell proliferation, actin cytoskeleton architecture and cell functionality, the induction of reactive oxygen species formation and effects on cell activation and differentiation. In order to properly address these issues, not only the targeted cell types should be tested in vitro and in vivo but also additional control cell types. For every cell type tested, assay conditions should be optimized for the specific cell type and a careful consideration of required controls must be made. Under many circumstances, it is not safe to assume that nanoparticles tested for one cell type may perform similarly when used for the visualization of another cell type.
